Clinicopathologic characteristics and its association with survival outcomes in gastric cancer after D2 resection followed by S1 and oxaliplatin as adjuvant therapy
Nội dung chính của bài viết
Tóm tắt
There is limited data about the clinic-pathological features and the predictors of survival in gastric cancer patients who received adjuvant SOX post-operation in Vietnam. This study aimed to identify the correlation between clinic-pathological features and clinical outcomes for this population. From January 2019 to December 2023, 69 patients aged above 18 years old were diagnosed with gastric cancer and treated at the National Cancer Hospital Vietnam. Clinical findings, histo-pathological parameters and outcomes were reviewed retrospectively. Clinic-pathological characteristics of the study population showed a predominance of males (60.8%), aged above 60 (52.17%), good performance status, undifferentiated tumour (68.12%), antrum cancers (86.96%), and lymph nodes involvement (75.36 %). The estimated 1-year, 2-year, 3-year overall survival (OS) and disease free survival (DFS) were 92.6%, 77.7%, 74.9% and 80.9%, 72.5% and 72.5%, respectively with the median follow-up period of 17 months. A significant prognostic predictor for survival was the presence of lymph node invasion (p = 0.0167) in a univariate analysis. Gastric cancer patients with adverse prognostic factors (node-positive) have a poor prognoses. Adjuvant chemotherapy may be more beneficial for these patients.
Chi tiết bài viết
Từ khóa
Gastric cancer, prognosis, adjuvant SOX
Tài liệu tham khảo
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Roder JD, Bottcher K, Siewert JR, et al. Prognostic factors in gastric carcinoma. Results of the Ger-man Gastric Carcinoma Study 1992. Cancer. 1993;72:2089-97.
4. Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer. 1989;64:2053-62.
5. Mitsudomi T, Matsusaka T, Wakasugi K, et al. A clinicopathological study of gastric cancer with special reference to age of the patients: an analysis of 1,630 cases. World J Surg. 1989;13:225-30.
6. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387-93.
7. Noh SH, Park SR, Yang H-K, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-96.
8. Maeta M, Yamashiro H, Oka A, et al. Gastric cancer in the young, with special reference to 14 pregnancy-associated cases: analysis based on 2,325 consecutive cases of gastric cancer. J Surg Oncol. 1995;58:191-5.
9. Kim DY, Ryu SY, Kim YJ, et al. Clinicopathological characteristics of gastric carcinoma in young patients. Langenbecks Arch Surg. 2003;388:245-9.
10. Hsieh FJ, Wang YC, Hsu JT, et al. Clinicopatho-logical features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012;105:304-9.
11. Choi JH, Chung HC, Yoo NC, et al. Gastric cancer in young patients who underwent curative resec-tion. Comparative study with older patients. Am J Clin Oncol. 1996;19:45-8.
12. Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3:15-8.
13. Milne AN, Offerhaus GJ. Early-onset gastric cancer: learning lessons from the young. World J Gastrointest Oncol. 2010;2:59-64.
14. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 1994;54:1941s-3s.
15. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101-12.
16. Bing Hu, Nassim El Hajj, Scott Sittler, et al. Gastric cancer: Classification, histology and application of molecular pathology. Journal of gastrointestinal oncology. 2012;3(3).
17. Yoshikawa K, Maruyama K. Characteristics of gastric cancer invading to the proper muscle layer--with special reference to mortality and cause of death. Jpn J ClinOncol. 1985;15:499-503.
18. Kulig J, Popiela T, Kolodziejczyk P, et al. Clinicopathological profile and long-term outcome in young adults with gastric cancer: multicenter evaluation of 214 patients. Langenbecks Arch Surg. 2008;393:37-43.
19. Eguchi T, Takahashi Y, Yamagata M, et al. Gastric cancer in young patients. J Am Coll Surg. 1999;188:22-6.
20. Bołdys H, Marek TA, Wanczura P, et al. Even young patients with no alarm symptoms should undergo endoscopy for earlier diagnosis of gastric cancer. Endoscopy. 2003;35:61-7.
21. Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer. 2017;20(1):175-81.
22. Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18(547). https://doi.org/10.1186/s12885-018-4480-9